Clinical trials: Vomiting
Nausea and Vomiting, Obesity
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one…
- Trial name
- NCT07446439
- Testing
- Tradipitant
- Where
- 10 sites in United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Vomiting, Diarrhea
Developing World Study for RotaTeq™ (V260-015)(COMPLETED)
The purpose of the current study is to evaluate whether the vaccine is effective, well-tolerated and immunogenic among infants in developing countries.
- Conditions
- Vomiting, Diarrhea, Fever
- Trial name
- NCT00362648
- Testing
- RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent
- Volunteers
- 7,504 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
Phase II Proof-of-concept Study of APD421
Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin
- Trial name
- NCT01303978
- Testing
- APD421
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 51 people
- Sponsor
- Acacia Pharma Ltd
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo…
- Trial name
- NCT03420781
- Testing
- Relamorelin
- Where
- 337 sites in United States, Argentina and 24 more
- Volunteers
- 467 people
- Sponsor
- Allergan
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting
The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients
- Trial name
- NCT00642499
- Testing
- Dronabinol
- Where
- 36 sites in United States
- Volunteers
- 103 people
- Sponsor
- Solvay Pharmaceuticals
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Post-Operative Nausea And Vomiting Study In Female Patients
The primary purpose of this study is to determine an effective dose of this NK-1 anti-emetic medication to prevent nausea and vomiting in females after surgery.
- Trial name
- NCT00274690
- Testing
- GW679769
- Where
- 44 sites in United States, Denmark and 9 more
- Volunteers
- 435 people
- Sponsor
- GlaxoSmithKline
Prevention of Postoperative Nausea and Vomiting
A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and Vomiting
The study is being conducted to evaluate the efficacy of HRS5580 for injection combined with palonosetron hydrochloride in the prevention of postoperative nausea and vomiting, and to explore the effective dose of HRS5580 for…
- Trial name
- NCT07709897
- Testing
- HRS5580 for injection combined with palonosetron hydrochloride;, HRS5580 for injection combined with palonosetron hydrochloride, HRS5580 for injection blank preparation combined with palonosetron hydrochloride
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Post-operative Nausea and Vomiting
Mass-balance Study of [14C]-APD421 in Healthy Volunteers
Open-label, non-randomised, single dose study in 6 healthy male subjects to assess the mass balance recovery, metabolite profile, metabolite identification and pharmacokinetics of 14C-labelled APD421
- Trial name
- NCT02881840
- Testing
- 14C-APD421
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Acacia Pharma Ltd
Chemotherapy-Induced Nausea and Vomiting
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
This Canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of Akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology…
- Trial name
- EVOLVE_CINV (NCT03649230)
- Testing
- 300mg netupitant/0.5mg palonosetron hydrochloride
- Where
- 17 sites in Canada
- Volunteers
- 207 people
- Sponsor
- Purdue Pharma, Canada
Pain, Nausea
A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)
The objectives of this study are to compare the occurrence and severity of opioid-induced nausea and vomiting (OINV) associated with CL-108 to Norco®, and to demonstrate the efficacy of CL-108 when compared to placebo for the…
- Conditions
- Pain, Nausea, Vomiting
- Trial name
- NCT02462811
- Testing
- CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)
- Where
- United States
- Volunteers
- 552 people
- Sponsor
- Joseph Hazelton
Postoperative Nausea and Vomiting
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
The primary objective of this study is to evaluate the efficacy of a single palonosetron IV dose compared to a single ondansetron IV dose in the prevention of postoperative nausea and vomiting through 24 hours after surgery in…
- Trial name
- NCT01395901
- Testing
- Palonosetron, Ondansetron
- Where
- 44 sites in United States, Argentina and 6 more
- Volunteers
- 670 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
The purpose of this study is to evaluate the efficacy and safety of fosaprepitant (MK-0517) plus ondansetron versus ondansetron alone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric participants…
- Trial name
- NCT02519842
- Testing
- Fosaprepitant, Ondansetron, Dexamethasone
- Volunteers
- 75 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV)
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV), Postoperative Nausea and Vomiting
- Trial name
- NCT07868861
- Testing
- NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Chemotherapy-Induced Nausea and Vomiting (CINV)
Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)
This study will evaluate if the mean value of brain neurokinin 1 (NK1)-receptor occupancy of participants treated with aprepitant is similar to that of participants treated with fosaprepitant at certain timepoints.
- Trial name
- NCT01111851
- Testing
- Fosaprepitant 150 mg, Aprepitant 165 mg, Aprepitant 250 mg
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Nausea and Vomitting
A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)
This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS). The main aims of this study are as follows: To check for side effects from treatment with TAK-951.
- Trial name
- NCT06768658
- Testing
- TAK-951
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Takeda